ResultsIQ

ResultsIQ › Latest results › Jagsonpal Pharmaceuticals Limited

Jagsonpal Pharmaceuticals Limited Q2 FY26 earnings call summary

NSE: JAGSNPHARM · BSE: 507789

Earnings call of 4 Nov 2025, summarised by AI from the filing.

Jagsonpal Q2 FY26 revenue ₹74.5 cr, PAT ₹12.6 cr up 10% year-on-year, with 10% growth guidance for the year.

Key takeaways

  1. Guidance Management targets about 10% growth for this year and low double-digit growth for the rest of the year.
  2. Growth drivers Legacy brand refresh like Indocap P and new products in difficult categories, plus MR productivity improvement.
  3. Risk Therapies and markets Jagsonpal operates in grew slower at 2.5% to 3% in Q2 FY26.

Original filing on BSE

Jagsonpal Pharmaceuticals Limited Q1 FY27 results

As filed: Revenue ₹82.2 cr (+8% year on year), EBITDA ₹17.2 cr (+33% year on year), PAT ₹13.2 cr (+20% year on year), EBITDA margin 21.0% (+386 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹64.2 cr (+9% year on year), EBITDA ₹11.2 cr (+40% year on year), PAT ₹8.8 cr (+25% year on year), EBITDA margin 17.4% (+382 bps). Score 38 of 100, Below trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin rose 382 bps year on year. Other income 27% of PBT. Revenue fell 12% from last quarter. Share price after the results: +2.6% in 30 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹73.0 cr (−1% year on year), EBITDA ₹16.3 cr (+2% year on year), PAT ₹11.0 cr (+4% year on year), EBITDA margin 22.3% (+68 bps). Score 41 of 100, In line with trend. Revenue, EBITDA and profit before exceptional items growth were below the company's own trend. EBITDA margin rose 68 bps year on year. Share price after the results: +5.4% in 30 days (Nifty 500: +2.5%).
  • Q2 FY26: Revenue ₹74.0 cr (−1% year on year), EBITDA ₹16.0 cr (+7% year on year), PAT ₹13.0 cr (+18% year on year), EBITDA margin 21.6% (+162 bps). Score 41 of 100, In line with trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin rose 162 bps year on year. Share price after the results: −4.7% in 30 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹76.0 cr (+25% year on year), EBITDA ₹13.0 cr (+30% year on year), PAT ₹11.0 cr (+120% year on year), EBITDA margin 17.1% (+71 bps). Score 65 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was below it. EBITDA margin rose 71 bps year on year. Share price after the results: −9.4% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹59.0 cr (+37% year on year), EBITDA ₹8.0 cr (+167% year on year), PAT ₹7.0 cr (+75% year on year), EBITDA margin 13.6% (+658 bps). Score 57 of 100, In line with trend. Revenue and EBITDA growth were above the company's own trend; profit growth was in line with it. EBITDA margin rose 658 bps year on year. Other income 33% of PBT. Revenue fell 20% from last quarter. Share price after the results: −2.8% in 30 days (Nifty 500: +4.5%).
  • Q3 FY25: Revenue ₹74.0 cr (+57% year on year), EBITDA ₹16.0 cr (+300% year on year), PAT ₹32.0 cr (+220% year on year), EBITDA margin 21.6% (+1,000 bps). Score 100 of 100, Above trend. EBITDA margin rose 1000 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹75.0 cr, EBITDA ₹15.0 cr, PAT ₹11.0 cr, EBITDA margin 20.0%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

Jagsonpal Pharmaceuticals Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.